Covid-19: the poorest risk of being "trampled in the rush on vaccines", warns WHO

"

" the WHO boss warned on Monday, November 23, the very day a third vaccine against Covid-19 showed promising preliminary results.

Read also: Covid-19: the European Union reserves nearly two billion doses of vaccines

“

”CEO Tedros Adhanom Ghebreyesus told the now traditional conference. WHO press.

After Pfizer-BioNTech and Moderna it was Monday the turn of the AstraZeneca-Oxford tandem to publish preliminary results of its vaccine which is in phase III of human trials.

The latter has been shown to be between 70 and 90% effective depending on how it is administered.

The first two showed an effectiveness of 95% also according to preliminary results.

The advantage of the AstraZeneca-Oxford vaccine is that it can be stored at temperatures of a few degrees while the other two require ultra-low temperatures.

Russia and China are also conducting trials with each a nationally developed vaccine.

To prevent the richest countries from buying all the doses of vaccines which in the first months will only be available in limited quantities, the WHO has set up a mechanism called the ACT-Accelerator which should make it possible to distribute the vaccine equitably. vaccines and other possible treatments.

But for that it takes 4.3 billion dollars immediately, recalled Dr Tedros and it will take 23.8 more next year.

The G20 leaders promised Sunday to "

" to guarantee equitable access to vaccines against the Covid-19, a voluntarism however tempered by statements by Angela Merkel in particular, "

" by the slow progress in matter.

"

" they write in their final declaration.

>> SEE ALSO -

Vaccination before Christmas?

"Today, hospitals are not associated with the vaccine deployment strategy", answers Frédéric Valletoux